

Atty Dkt. No.: THUR-001  
USSN: 09/582,964

### **AMENDMENTS**

Claims 1-42 (canceled).

43. (Previously Presented) A method of treating a host suffering from epilepsy, said method comprising:

administering to said host known to suffer from epilepsy an amount of a serine protease inhibitor effective to treat said host for said epilepsy.

44. (Canceled)

45. (Canceled)

46. (Previously presented) The method according to Claim 43, wherein said method results in a decrease in seizure proneness.

47. (Previously presented) The method according to Claim 43, wherein said host is a mammalian host.

Claims 48 - 50 (Canceled)

51. (Previously Presented) A method of preventing the onset of epilepsy, which method comprises:

administering to said host an amount of a serine protease inhibitor effective to prevent onset of said epilepsy.

52. (Canceled)

53. (Canceled)

Atty Dkt. No.: THUR-001  
USSN: 09/582,964

54. (Previously presented) The method according to Claim 51, wherein said host is a mammalian host.

55. (Previously Presented) The method of Claim 43, wherein said serine protease inhibitor is an inhibitor of trypsin-like serine proteases.

56. (Previously Presented) The method of Claim 55, wherein serine protease inhibitor is a tPA inhibitor.

57. (Previously Presented) The method of Claim 51, wherein said serine protease inhibitor is an inhibitor of trypsin-like serine proteases.

58. (Previously Presented) The method of Claim 57, wherein said serine protease inhibitor is a tPA inhibitor.

Please enter the following new claims:

59. (New) The method of Claim 43, wherein said serine protease reduces protease-catalyzed cleavage of CAMS.

60. (New) The method of Claim 43, wherein said serine protease inhibitor is AEBSF.

61. (New) The method of Claim 43, wherein said serine protease inhibitor is present in an amount ranging from about 0.1 to 50 mgs/kg.